Streetbeat News

PROK

ProKidney Corp.

https://www.prokidney.com

Industry

Biotechnology

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Open

2.18

Mkt cap

491M

Volume

692K

High

2.18

P/E Ratio

-2.73

52-wk high

4.44

Low

1.69

Div yield

N/A

52-wk low

1.12

ProKidney Corp. reported its third quarter 2024 financial results and provided updates on regulatory and clinical developments following a successful FDA Type B meeting.

Portfolio Pulse from

November 12, 2024 | 12:45 pm

ProKidney Corp. (NASDAQ:PROK) will present five posters, including a late-breaking clinical trial, at ASN Kidney Week 2024. The presentations will focus on their cell therapy candidate, Rilparencel, for chronic kidney disease (CKD) and its effects on patients with diabetes and advanced CKD.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 11:33 am

JP Morgan has initiated coverage on ProKidney with a Neutral rating, indicating a balanced outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:30 pm

ProKidney shares rose following Guggenheim's initiation of coverage with a Buy rating and a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:55 am

Guggenheim has initiated coverage on ProKidney with a Buy rating and set a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 9:47 am

B of A Securities has maintained a Neutral rating on ProKidney (NASDAQ:PROK) but has lowered its price target from $4 to $3.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 12:08 pm

ProKidney is prioritizing its PROACT 1 trial and discontinuing PROACT 2, which was focused on non-U.S. enrollment. This decision is expected to extend their cash runway to Q1 2027 and reduce expenses by $150-$175 million. The company anticipates FDA approval for rilparencel through an expedited pathway.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:39 am

ProKidney (NASDAQ:PROK) reported Q2 EPS of $(0.16), beating the $(0.17) estimate. The company ended the quarter with $431.5M in cash and equivalents, despite a 14.29% increase in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 11:17 am

The article highlights notable insider trades in three companies: PBF Energy, Citi Trends, and ProKidney. Insider purchases often indicate confidence in the company's prospects. PBF Energy's 10% owner acquired $30.83 million worth of shares, Citi Trends' 10% owner bought $2.07 million worth of shares, and ProKidney's 10% owner purchased $20 million worth of shares.

Portfolio Pulse from Avi Kapoor

June 26, 2024 | 12:37 pm

ProKidney has announced an upsized public offering of $130 million, involving 53,719,009 Class A ordinary shares priced at $2.42 per share. The offering is expected to close around June 13, 2024, pending customary closing conditions.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 6:25 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.